celltech r&d limited
celltech r&d limited Company Information
Company Number
01472269
Website
www.celltech.co.ukRegistered Address
208 bath road, slough, berkshire, SL1 3WE
Industry
Research and experimental development on biotechnology
Telephone
01473012238
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
celltech group ltd 100%
celltech r&d limited Estimated Valuation
Pomanda estimates the enterprise value of CELLTECH R&D LIMITED at £215.4m based on a Turnover of £88.2m and 2.44x industry multiple (adjusted for size and gross margin).
celltech r&d limited Estimated Valuation
Pomanda estimates the enterprise value of CELLTECH R&D LIMITED at £588.3k based on an EBITDA of £57k and a 10.32x industry multiple (adjusted for size and gross margin).
celltech r&d limited Estimated Valuation
Pomanda estimates the enterprise value of CELLTECH R&D LIMITED at £81.3m based on Net Assets of £37.8m and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Celltech R&d Limited Overview
Celltech R&d Limited is a live company located in berkshire, SL1 3WE with a Companies House number of 01472269. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in January 1980, it's largest shareholder is celltech group ltd with a 100% stake. Celltech R&d Limited is a mature, large sized company, Pomanda has estimated its turnover at £88.2m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Celltech R&d Limited Health Check
Pomanda's financial health check has awarded Celltech R&D Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 2 areas for improvement. Company Health Check FAQs
4 Strong
3 Regular
2 Weak
Size
annual sales of £88.2m, make it larger than the average company (£3.5m)
£88.2m - Celltech R&d Limited
£3.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 12%, show it is growing at a similar rate (14.1%)
12% - Celltech R&d Limited
14.1% - Industry AVG
Production
with a gross margin of 53%, this company has a comparable cost of product (53%)
53% - Celltech R&d Limited
53% - Industry AVG
Profitability
an operating margin of 0.1% make it more profitable than the average company (-0.4%)
0.1% - Celltech R&d Limited
-0.4% - Industry AVG
Employees
with 630 employees, this is above the industry average (44)
630 - Celltech R&d Limited
44 - Industry AVG
Pay Structure
on an average salary of £139.8k, the company has a higher pay structure (£77.9k)
£139.8k - Celltech R&d Limited
£77.9k - Industry AVG
Efficiency
resulting in sales per employee of £140k, this is equally as efficient (£136.2k)
£140k - Celltech R&d Limited
£136.2k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Celltech R&d Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Celltech R&d Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Celltech R&d Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 7 weeks, this is less cash available to meet short term requirements (35 weeks)
7 weeks - Celltech R&d Limited
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 5.6%, this is a lower level of debt than the average (50%)
5.6% - Celltech R&d Limited
50% - Industry AVG
CELLTECH R&D LIMITED financials
Celltech R&D Limited's latest turnover from December 2022 is £88.2 million and the company has net assets of £37.8 million. According to their latest financial statements, Celltech R&D Limited has 630 employees and maintains cash reserves of £316 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 88,170,000 | 89,554,000 | 71,910,000 | 62,869,000 | 59,302,000 | 55,407,000 | 50,567,000 | 42,435,000 | 39,422,000 | 39,688,000 | 37,669,000 | 34,321,000 | 32,170,000 | 43,943,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Cost Of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Gross Profit | 42,435,000 | 39,422,000 | 39,688,000 | 37,669,000 | 34,321,000 | 32,170,000 | 43,943,000 | |||||||
| Admin Expenses | 45,370,000 | 42,851,000 | 42,271,000 | 39,175,000 | 35,723,000 | 33,188,000 | 45,143,000 | |||||||
| Operating Profit | 57,000 | 59,000 | 85,000 | 85,000 | 87,000 | 84,000 | 86,000 | -2,935,000 | -3,429,000 | -2,583,000 | -1,506,000 | -1,402,000 | -1,018,000 | -1,200,000 |
| Interest Payable | 0 | 22,000 | 8,000 | 0 | 0 | 0 | 1,000 | 0 | 7,000 | 21,000 | 180,000 | 236,000 | 583,000 | 865,000 |
| Interest Receivable | 389,000 | 24,000 | 114,000 | 214,000 | 87,000 | 12,000 | 71,000 | 206,000 | 202,000 | 1,223,000 | 3,426,000 | 3,069,000 | 2,302,000 | 2,153,000 |
| Pre-Tax Profit | 446,000 | 61,000 | 191,000 | 299,000 | 170,000 | -30,000 | 292,000 | -2,813,000 | -3,236,000 | -1,253,000 | 3,725,000 | -413,000 | 116,000 | -962,000 |
| Tax | 682,000 | 1,367,000 | 5,708,000 | -573,000 | 2,518,000 | -5,308,000 | 1,065,000 | 3,769,000 | 4,600,000 | 141,000 | -1,834,000 | 10,291,000 | 9,014,000 | -8,532,000 |
| Profit After Tax | 1,128,000 | 1,428,000 | 5,899,000 | -274,000 | 2,688,000 | -5,338,000 | 1,357,000 | 956,000 | 1,364,000 | -1,112,000 | 1,891,000 | 9,878,000 | 9,130,000 | -9,494,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 11,612,000 | 0 | 1,500,000 | 0 | 12,000,000 | 6,500,000 | 0 | 5,000,000 |
| Retained Profit | 1,128,000 | 1,428,000 | 5,899,000 | -274,000 | 2,688,000 | -5,338,000 | -10,255,000 | 956,000 | -136,000 | -1,112,000 | -10,109,000 | 3,378,000 | 9,130,000 | -14,494,000 |
| Employee Costs | 88,094,000 | 86,220,000 | 71,809,000 | 62,769,000 | 59,772,000 | 57,471,000 | 50,567,000 | 45,362,000 | 42,845,000 | 42,271,000 | 39,175,000 | 35,723,000 | 33,188,000 | 43,843,000 |
| Number Of Employees | 630 | 629 | 585 | 530 | 501 | 486 | 448 | 412 | 420 | 434 | 439 | 414 | 409 | 523 |
| EBITDA* | 57,000 | 59,000 | 85,000 | 85,000 | 87,000 | 84,000 | 86,000 | -2,935,000 | -3,429,000 | -2,583,000 | -1,506,000 | -1,402,000 | -1,018,000 | -1,200,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 33,753,000 | 35,075,000 | 32,332,000 | 52,212,000 | 41,120,000 | 34,682,000 | 32,187,000 | 81,180,000 | 79,553,000 | 76,689,000 | 85,301,000 | 100,015,000 | 111,415,000 | 117,158,000 |
| Misc Debtors | 5,958,000 | 9,021,000 | 7,155,000 | 3,389,000 | 8,476,000 | 8,143,000 | 4,508,000 | 7,744,000 | 5,134,000 | 0 | 0 | 0 | 0 | 0 |
| Cash | 316,000 | 494,000 | 513,000 | 494,000 | 501,000 | 500,000 | 510,000 | 8,635,000 | 7,245,000 | 6,207,000 | 387,000 | 393,000 | 327,000 | 338,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 40,027,000 | 44,590,000 | 40,000,000 | 56,095,000 | 50,097,000 | 43,325,000 | 37,205,000 | 97,559,000 | 91,932,000 | 82,896,000 | 85,688,000 | 100,408,000 | 111,742,000 | 117,496,000 |
| total assets | 40,027,000 | 44,590,000 | 40,000,000 | 56,095,000 | 50,097,000 | 43,325,000 | 37,205,000 | 97,559,000 | 91,932,000 | 82,896,000 | 85,688,000 | 100,408,000 | 111,742,000 | 117,496,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,173,000 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 8,000 | 411,000 | 3,000 | 175,000 | 0 | 0 | 44,000 | 50,481,000 | 51,101,000 | 50,356,000 | 50,546,000 | 60,936,000 | 77,147,000 | 93,147,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,236,000 | 3,925,000 | 3,035,000 | 6,310,000 | 3,475,000 | 5,462,000 | 77,000 | 80,000 | 64,000 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 2,244,000 | 4,336,000 | 3,038,000 | 6,485,000 | 3,475,000 | 5,462,000 | 121,000 | 50,561,000 | 51,165,000 | 50,356,000 | 54,719,000 | 60,936,000 | 77,147,000 | 93,147,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 2,244,000 | 4,336,000 | 3,038,000 | 6,485,000 | 3,475,000 | 5,462,000 | 121,000 | 50,561,000 | 51,165,000 | 50,356,000 | 54,719,000 | 60,936,000 | 77,147,000 | 93,147,000 |
| net assets | 37,783,000 | 40,254,000 | 36,962,000 | 49,610,000 | 46,622,000 | 37,863,000 | 37,084,000 | 46,998,000 | 40,767,000 | 32,540,000 | 30,969,000 | 39,472,000 | 34,595,000 | 24,349,000 |
| total shareholders funds | 37,783,000 | 40,254,000 | 36,962,000 | 49,610,000 | 46,622,000 | 37,863,000 | 37,084,000 | 46,998,000 | 40,767,000 | 32,540,000 | 30,969,000 | 39,472,000 | 34,595,000 | 24,349,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 57,000 | 59,000 | 85,000 | 85,000 | 87,000 | 84,000 | 86,000 | -2,935,000 | -3,429,000 | -2,583,000 | -1,506,000 | -1,402,000 | -1,018,000 | -1,200,000 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | 682,000 | 1,367,000 | 5,708,000 | -573,000 | 2,518,000 | -5,308,000 | 1,065,000 | 3,769,000 | 4,600,000 | 141,000 | -1,834,000 | 10,291,000 | 9,014,000 | -8,532,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -4,385,000 | 4,609,000 | -16,114,000 | 6,005,000 | 6,771,000 | 6,130,000 | -52,229,000 | 4,237,000 | 7,998,000 | -8,612,000 | -14,714,000 | -11,400,000 | -5,743,000 | 117,158,000 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | -1,689,000 | 890,000 | -3,275,000 | 2,835,000 | -1,987,000 | 5,385,000 | -3,000 | 16,000 | 64,000 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 3,435,000 | -2,293,000 | 18,632,000 | -3,658,000 | -6,153,000 | -5,969,000 | 53,377,000 | -3,387,000 | -6,763,000 | 6,170,000 | 11,374,000 | 20,289,000 | 13,739,000 | |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -403,000 | 408,000 | -172,000 | 175,000 | 0 | -44,000 | -50,437,000 | -620,000 | 745,000 | -190,000 | -10,390,000 | -16,211,000 | -16,000,000 | 93,147,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 389,000 | 2,000 | 106,000 | 214,000 | 87,000 | 12,000 | 70,000 | 206,000 | 195,000 | 1,202,000 | 3,246,000 | 2,833,000 | 1,719,000 | 1,288,000 |
| cash flow from financing | -3,613,000 | 2,274,000 | -18,613,000 | 3,651,000 | 6,158,000 | 6,085,000 | -50,026,000 | 4,861,000 | 9,303,000 | 3,695,000 | -5,538,000 | -11,879,000 | -13,165,000 | 133,278,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -178,000 | -19,000 | 19,000 | -7,000 | 1,000 | -10,000 | -8,125,000 | 1,390,000 | 1,038,000 | 5,820,000 | -6,000 | 66,000 | -11,000 | 338,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,173,000 | 4,173,000 | 0 | 0 | 0 |
| change in cash | -178,000 | -19,000 | 19,000 | -7,000 | 1,000 | -10,000 | -8,125,000 | 1,390,000 | 1,038,000 | 9,993,000 | -4,179,000 | 66,000 | -11,000 | 338,000 |
celltech r&d limited Credit Report and Business Information
Celltech R&d Limited Competitor Analysis
Perform a competitor analysis for celltech r&d limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
celltech r&d limited Ownership
CELLTECH R&D LIMITED group structure
Celltech R&D Limited has no subsidiary companies.
Ultimate parent company
UCB SA
#0001505
2 parents
CELLTECH R&D LIMITED
01472269
celltech r&d limited directors
Celltech R&D Limited currently has 3 directors. The longest serving directors include Mr Yogesh Khatri (Jun 2013) and Claire Brading (Jan 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Yogesh Khatri | England | 58 years | Jun 2013 | - | Director |
| Claire Brading | England | 42 years | Jan 2021 | - | Director |
| Olufunlayo Oluwa | 56 years | Jan 2024 | - | Director |
P&L
December 2022turnover
88.2m
-2%
operating profit
57k
-3%
gross margin
53%
+3.36%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
37.8m
-0.06%
total assets
40m
-0.1%
cash
316k
-0.36%
net assets
Total assets minus all liabilities
celltech r&d limited company details
company number
01472269
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
January 1980
age
44
accounts
Full Accounts
ultimate parent company
previous names
celltech chiroscience limited (April 2001)
celltech therapeutics limited (May 2000)
See moreincorporated
UK
address
208 bath road, slough, berkshire, SL1 3WE
last accounts submitted
December 2022
celltech r&d limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to celltech r&d limited.
celltech r&d limited Companies House Filings - See Documents
| date | description | view/download |
|---|
